Search alternatives:
largest decrease » marked decrease (Expand Search)
values decrease » values increased (Expand Search)
larger decrease » marked decrease (Expand Search)
large decrease » marked decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
Showing 141 - 160 results of 1,252 for search '(( ct ((values decrease) OR (largest decrease)) ) OR ( c ((large decrease) OR (larger decrease)) ))', query time: 0.35s Refine Results
  1. 141
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  2. 142
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  3. 143
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  4. 144
    Overview of the six original ACTIV-3/TICO trials.

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    “…However, there is concern that by neutralizing the SARS-CoV-2 virus, nMAbs may decrease the availability of antigens to the immune system, potentially impairing the endogenous polyclonal immune response and decreasing long-term immune protection.…”
    Save to List
    Saved in:
  5. 145
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  6. 146
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  7. 147
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  8. 148
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  9. 149
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  10. 150
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  11. 151
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  12. 152
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  13. 153
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  14. 154
    Partial dependence plots.

    Partial dependence plots. by Andrew Kulmatiski (833256)

    Published 2025
    Save to List
    Saved in:
  15. 155
    Serum concentrations of malondialdehyde (a) and super oxide dismutase (b) and NOx (nitrate +nitrite) (c) in different experimental groups on day 2 and 10.

    Serum concentrations of malondialdehyde (a) and super oxide dismutase (b) and NOx (nitrate +nitrite) (c) in different experimental groups on day 2 and 10. by Omid Mehrpour (9385929)

    Published 2024
    Save to List
    Saved in:
  16. 156
    Replication of YFV-17D cap1 and cap0 in C6/36 cells.

    Replication of YFV-17D cap1 and cap0 in C6/36 cells. by Anja vom Hemdt (19787189)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  17. 157
    Posterior estimates of niche overlap for predators.

    Posterior estimates of niche overlap for predators. by Nathan D. McTigue (10706460)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 158
    Posterior estimates of niche overlap for deposit feeders.

    Posterior estimates of niche overlap for deposit feeders. by Nathan D. McTigue (10706460)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 159
    Niche overlap within shelf communities.

    Niche overlap within shelf communities. by Nathan D. McTigue (10706460)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 160
    Sampling locations across the Arctic where data were aggregated.

    Sampling locations across the Arctic where data were aggregated. by Nathan D. McTigue (10706460)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: